Recent Press Releases

Allergan Issues Voluntary Nationwide Recall in the U.S. of Specific Lots of REFRESH® Lacri-Lube®, REFRESH P.M. ®, FML® (fluorometholone ophthalmic ointment) 0.1%, and Blephamide® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%

FOR IMMEDIATE RELEASE - DUBLIN, IRELAND – Aug. 24, 2015 – Allergan plc, today announced that it is conducting a voluntary recall down to consumer level of specific lots of its...

Expert committee BACKS Hospira's InflectraTM

Comparable, safety and efficacy of first mAb biosimilar therapy confirmed by TGA and PBAC Melbourne, Australia, Aug. 21, 2015 –The PBAC today recommended that InflectraTM (infliximab),1 the...

Depomed's Board of Directors Unanimously Rejects Revised Proposal from Horizon Pharma plc

Horizon's Proposal Has Current Value Below $30 Per Share, Which Is Less Than Prior Proposal NEWARK, Calif., Aug. 19, 2015 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the...

FDA's Big Mistake: Expect Flibanserin to Be Pulled From the Market in a Few Years

Statement of Dr. Sidney Wolfe, Founder and Senior Adviser, Public Citizen's Health Research Group Note: Dr. Sidney Wolfe, founder and senior adviser of Public Citizen's Health Research Group,...

Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals

Enters Sexual Health Market with FDA-Approved Addyi™ (flibanserin 100mg) Addyi Expected to Launch in U.S. in the Fourth Quarter of 2015 LAVAL, Quebec and RALEIGH, N.C., Aug. 20, 2015...

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

RIDGEFIELD, Conn and INDIANAPOLIS, Aug. 20, 2015 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from EMPA-REG OUTCOME®. This...

Novartis drug Odomzo® gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients

Approval follows positive CHMP opinion based on pivotal Phase II study showing durable objective response rate per central review of 56% in patients with laBCC[1] Basal cell carcinoma is the most...

Hospira's Inflectra™ registered in Australia

Melbourne, Australia, Aug 20, 2015 – Hospira today announced that Inflectra™ (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This...

Horizon Pharma plc to Amend Preliminary Solicitation Statement to Include Proposed Nominees for Depomed's Board

Horizon Pharma plc to Amend Preliminary Solicitation Statement to Include Proposed Nominees for Depomed's Board Horizon Pharma Intends to Seek Election of Its Slate at Special Meeting; Horizon...

Cushman & Wakefield releases N.J. Pharma/Life Sciences Market Report

Cushman & Wakefield of New Jersey, Inc. One Meadowlands Plaza East Rutherford, New Jersey 07073 Media Contact: Evelyn Weiss Francisco: evelyn@caryl.com, (201) 796-7788...

Major restructuring to regain profitability and ensure value creation

Valby, Denmark, 2015-08-19 07:42 CEST (GLOBE NEWSWIRE) -- Lundbeck is initiating a restructuring programme which will reduce the total cost base by approximately DKK 3 billion with full effect in...

Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem Cell Transplantation Consolidation

-FDA Approval Based on the Phase 3 AETHERA Clinical Trial Results- -AETHERA Trial Also Converts Prior Accelerated Approval to Regular Approval in Treatment of Classical Hodgkin Lymphoma Patients who...

New data show Spiolto® Respimat® provides meaningful quality of life improvements in COPD

Ingelheim, Germany, 17th August 2015 — Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO® 1&2 trials (NCT01964352/NCT02006732), which show...

AMAG Pharmaceuticals Completes Acquisition of Cord Blood Registry

Expands company's growing maternal health business Transaction expected to be immediately accretive Company anticipates seamless integration and is well positioned for future acquisitions ...

Mylan Confirms First-to-File Patent Challenge Relating to Zytiga(R)

HERTFORDSHIRE, England and PITTSBURGH, Aug. 18, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today confirmed that the company has been sued by BTG International Ltd., Janssen Biotech, Inc., Janssen...

FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Merck's Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a...

Endo Announces U.S. District Court Ruling Upholding OPANA(R) ER Intellectual Property

DUBLIN, Aug. 14, 2015 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that the U.S. District Court for the Southern District of New York has issued a ruling upholding...

Perrigo Comments On Mylan's Reckless Lowering Of Tender Threshold

DUBLIN, Aug. 13, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo," "the Company") (NYSE: PRGO; TASE) today responded to the announcement that Mylan N.V. ("Mylan") has...

Mylan Responds to ISS Recommendation Regarding Perrigo Transaction

HERTFORDSHIRE, England and PITTSBURGH, Aug. 14, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today issued the following statement in response to the report issued by Institutional Shareholder...

Wuxi Pharmatech Enters Into Definitive Merger Agreement

SHANGHAI, Aug. 14, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (WX), a leading open-access R&D capability and technology platform company...